The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
|Videos|June 19, 2022
How Infusion Centers Support Dermatology Research
Author(s)Linda Stocum, Associate Editor
Lindsey Savickas, RN, BSN, and COO at Infusion Associates, explains how infusion centers can support researchers in the dermatology space in discovering more effective treatments.
Advertisement
Advertisement
Related to this article
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
FDA Revises TB Evaluation Guidance for SKYRIZI
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
5